Analysts Divided On Sarepta Muscular Dystrophy Drug Outcome After FDA Delay

Shares of Sarepta Therapeutics are sharply higher following the announcement that the U.S. Food and Drug Administration extended its review of the company's eteplirsen for the treatment of Duchenne muscular dystrophy.